Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular drug

This page shows the latest cardiovascular drug news and features for those working in and with pharma, biotech and healthcare.

Evenity back on track with FDA panel blessing in osteoporosis

Evenity back on track with FDA panel blessing in osteoporosis

While the FDA still has the final say on full approval, the bone-building drug seems to have finally shaken off the cardiovascular safety concerns that caused the agency to reject ... to a much higher risk of cardiovascular side effects than the

Latest news

More from news
Approximately 2 fully matching, plus 76 partially matching documents found.

Latest Intelligence

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases. ... We’re already seeing evidence of how AI can positively impact drug discovery.

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration ... centric means that you need to think about your patients

  • Interview: Peter Meeus, Novo Nordisk Interview: Peter Meeus, Novo Nordisk

    Several obstacles stand in the way of the uptake of Tresiba in Europe, including the decision from the US FDA to request more data from Novo Nordisk regarding the drug's ... cardiovascular safety before it can be approved.

  • Pharma deals during October 2012 Pharma deals during October 2012

    In return for granting Merck a global exclusive licence to its cardiovascular drug candidates, Theravance will receive $153m in R&D funding and milestone payments, including a $5m upfront payment and ... and manufacturing partner. Quillivant XR is based

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... 168. Vestiq / BioAlliance (a). Licence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Sanifit appoints Alexander Gold chief medical officer Sanifit appoints Alexander Gold chief medical officer

    Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others. ... A cardiologist with over 16 years experience of drug

  • Senior AstraZeneca exec jumps ship to small biotech Senior AstraZeneca exec jumps ship to small biotech

    AstraZeneca's chief executive, Pascal Soriot, will take over the job of late-stage drug development on an interim basis, according to news reports. . ... Meanwhile Elisabeth Björk, an associate professor of medicine at Uppsala university and leads

  • Milestone names chief medical officer Milestone names chief medical officer

    Cardiovascular specialist Milestone Pharmaceuticals has appointed experienced pharma researcher Dr Francis Plat as its new chief medical officer. ... Milestone's CEO Philippe Douville said: "Dr Plat is the perfect candidate for our development program

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    He also served for four years as the industry representative to the FDA's Cardiovascular and renal Drug Products Advisory Committee. ... By translating the groundbreaking science of the founding investigators into effective, disease modifying treatments,

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Packer Forbes News November 2015

    A graduate from the University of Bath, Lydia’s study areas included Cardiovascular Pharmacology, Regenerative Medicine, Drug Targets in the Immune System with her dissertation focusing on the possibility of a

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics